Dr. Kun Meng is Chairman & CEO of Shenogen Pharma Group. He has more than 15-year research experience in molecular biology, small molecule drug and pharmacology, as well as over 10-year experience of drug development and management in pharma industry. He is familiar with the overall process of drug R&D ranging from research to clinic, from market to venture. He also stays in touch with the latest progress in biopharma domestic and abroad. He maintains a broad network with researchers, industrialists, entrepreneurs and investors. Dr. Meng was CEO of a traditional Chinese medicine technology company and Chief Technical Officer of Jianxin Pharmaceuticals Co., Ltd. Dr. Meng received Ph.D. degree of Biochemistry from Chinese Academy of Sciences. He completed postdoctoral training in Harvard and Washington University School of Medicine, and he also received MPA degree from Kennedy School at Harvard. Dr. Meng was Beijing High-level Talents Organization and Beijing Scientific Leader Program.

Dr. Baoping Wang is Chief Operation Officer of Shenogen Pharma Group. Dr. Wang has 15-year research experience in molecular biology and immunology followed by 20 years’ experience in novel drug research and development and management of R&D operations. He received a BS degree in Applied Chemistry from Shanghai Jiao Tong University and a PhD in Genetics from University of Minnesota. He completed his postdoc research at Harvard Medical School where he then served as an Instructor and Assistant Professor, and author/co-authored approx. 30 peer-reviewed publications and one patent. He returned China in 1998 to join industry. Since 2001, he has been the head of Novo Nordisk R&D center China,has been responsible for the R&D center’s overall operations and site management, and played a pivotal role in developing the center to be one of the largest R&D centers by multinational pharmaceutical companies in China, and an important site of Novo Nordisk R&D organization. He is a vice president of Novo Nordisk R&D and from 2011 till now the President of Novo Nordisk Research Center China.


Dr. Charlie Wang is Chief Science Officer of Shenogen Pharma Group. He received Ph.D. degree from Washington University at St. Louis. He completed postdoctoral training in Princeton University, and was Assistant Professor of Harvard Medical School. Dr. Wang was a professor of pathology in Creighton University, director of an oncology laboratory when he founded Shenogen together with Dr. Kun Meng. Dr. Wang has over 20-year experience in cancer research. He is expert in molecular cancer biology, especially cell proliferation, differentiation and apoptosis. Dr. Wang is dedicated to study breast cancer related genes. He identified and cloned a novel membrane estrogen receptor ER-alpha 36 and studied its functions. His findings greatly contributed to the understanding of the pathogenesis of breast cancer, and got high remarks from Elwood Jensen, fellow of National Academy of Sciences and V. Craig Jordan, “Father of Tamoxifen”. Dr. Wang received grants from NIH, American Cancer Society, the US Department of Defense and Susan G. Komen Foundation. Dr. Wang has authored/ co-authored more than 70 peer-reviewed papers, host and attended many key scientific conferences, written four books and owned three granted patents. Dr. Wang returned China in 2014. He was elected into the Recruitment Program of Global Experts, Beijing Haiju Program and Shandong Taishan Academician Program.


Dr. Jian Peng is Senior Vice President of ShenogenPharma Group, responsible for regulatory affairs and drug development strategy. Dr. Peng has high reputation in drug regulatory and drug development, and has worked in the field for the last 20 years. Prior to joining Shenogen, he served as scientific advisor, director of clinical research & oncology head of Asia Pacific, Sanofi, sequentially. Before that, Dr. Peng was in charge of oncology drug approval in Center of Drug Evaluation (CDE), Chinese Food and Drug Administration (CFDA). He was lead director of the program for oncology drug clinical research and evaluation, which helped to improve quality of clinical trials in China. Dr. Peng played a key role in leading several Chinese first-in-class oncology drugs to approval, including Icotinib from BettaPharma, Apatinib from Heng Rui Medicine, Chidamide from Chipscreen. He was also the leader of Oxaliplatin (Sanofi) clinical trials and regulatory process in China. Dr. Peng got his PhD degree from China Pharmaceutical University and master degree from China Academy of Chinese Medicine Sciences. Dr. Peng is author/co-author of more than 20 SCI papers and serves as a member of Chinese Society of Clinical Oncology (CSCO). 


Dr. Hong Guo is the Chief Medical Officer and Vice President for Clinical Development of Beijing Shenogen Pharma Group.  Dr. Guo has more than 20 years of experience in clinical development, and has led many clinical research programs at several multinational pharmaceutical companies, including Novartis, GSK, Novo Nordisk, Pfizer, Merck and Bayer. He is very strong in the execution of clinical development and has insights in clinical trial practices.  Dr. Guo is well connected with oncology clinical trial PIs in many large hospitals in China, and led many successful Phase III oncology trial programs.  Prior to joining Shenogen, he was Novartis’ Global Monitoring Operation (GMO) Country Head for China, responsible for all of Novartis’ late stage oncology clinical programs and managed a 60+ oncology clinical development team. He earned his MD degree from the Capital Medical University and started his career as an anesthetist at the Beijing Chest Tumor Hospital, and later on received an MBA degree from the University of East London. He was a committee member for the 1st and 2nd China Pharmaceutical Conferences, and currently acts as the chairman for the RDPAC Clinical Operations, and team leader for the Inspection Task Force, responsible for communications with CFDI/CFDA, HGRAO/MOST and collaborations with the RA and QA teams in RDPAC for foreign companies.


Dr. Jun Bao is Senior Vice President and Chief Business Officer of Shenogen Pharma Group. He also serves as a member of board of directors as well as acting Chief Financial Officer. He is responsible for company’s business development, financing and corporate strategy. He has over 20 years of combined business and science experiences. He is well-experienced in the areas of new drug R&D, technology transfer, licensing and business development, venture investment and corporate financing. Before he joined Shenogen, Dr. Bao was Director, Worldwide Business Development, Head of China at GlaxoSmithKline (GSK), responsible for business development activities in China. Prior to GSK, he worked at Onyx Pharmaceuticals, ICOS Corporation and Cell Therapeutics as a business development executive with progressive responsibilities. Dr. Bao also worked as a finance manager in Procter & Gamble based in Cincinnati. He received a BS in Microbiology from Shandong University and a PhD in Neuroscience from University of Kansas. Dr. Bao completed his postdoctoral fellowship in Johns Hopkins University. In addition, he received an MBA in Finance from University of Chicago. He has authored/co-authored more than 30 research publications and co-founded two start-up biotech companies. Dr. Bao was also a board member of BayHelix.


Dr. Xiao Shang is a Senior Vice President of Shenogen Pharma Group, responsible for Antibody Drug Conjugate (ADC) and chemical development projects. He has nine years of work experience at Seattle Genetics, a leading ADC company in the world. At Seattle Genetics he was a team leader working on the discovery and optimization of production processes for critical raw materials, potent drugs and drug-linkers, and participated in non-commercial supply of critical starting materials, process optimization and scale-ups, GMP production, process validation, and large scale commercial manufacture. Dr. Shang supported the successful development of the world’s first highly specific and efficacious ADC (ADCETRIS) through the stages of preclinical studies, clinical trials and commercialization in just a few years and in the face of resourceconstrain.  Dr. Shang also supported many other internal ADC programs at Seattle Genetics and programs from many multinational big-pharma and biotechs, such as Pfizer, Roche-Genentech, Bayer, GSK, Abbott, Daiichi-Sankyo, Takeda. Before joining Seattle Genetics, he worked for Chiron and Sanofi-Aventis as research scientist in medicinal chemistry and process chemistry. Dr. Shang received his B.Sc.-Chemistry from Peking University and his Ph.D.-Organic Chemistry from University of Alberta. He completed his postdoctoral training at University of Toronto.  Dr. Shang won the Beijing High-Level Oversea Talents Award.


Dr. Zhu Yunxiang currently serves as senior vice president of biopharmaceutical  discovery and development. He is responsible for the company's research and development of antibody therapeutics for cancer immunotherapy and autoimmune diseases, especially for the development of multifunctional antibody biologics. Before joining Shenogen, Dr. Zhu served as a senior R&D director for the 3rd largest global biotech company Genzyme, late acquired by Sanofi, a global biopharmaceutical company where he engaged in new drug discovery for rare diseases and autoimmune diseases. He has nearly 18 years of experience in new drug discovery and development. He independently developed a new drug that is in Phase III clinical trials and is expected to apply for new drug approval in 2019. He also led the team and discovered two new candidate drugs which are in mid/later stage development. Dr. Zhu has more than ten years of experience in bispecific antibody drug discovery, with two proven new targets in genetic diseases and autoimmune diseases. Dr. Zhu graduated from the Department of Chemistry of Zhejiang University and obtained a master's degree from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, after which he worked at Fudan Institute of Genetics for two years. He received his Ph.D. in cell biology from University of Miami, School of Medicine in US, and completed his post-doctoral training at University of Washington, School of Medicine in St. Louis.  Dr. Zhu has published nearly 30 papers in top-notch scientific journals, including "Science " and " PNAS"; he also holds 12 issued US patents and nearly 40 global patents, with a number of pending patent applications.


Mr. Yongmao Liu is Executive Vice President of Shenogen Pharma Group, responsible for manufacturing and administrating. Mr. Liu was VP of Novozyme China and Novo Nordisk China. He was a deputy Manager of Northeast General Pharmaceutical Factory, deputy director of Shenyang Medicine Administration, vice president of Northeast Pharmaceuticals, President of China-Japan Shenyang Eisai Pharmaceutical Co., Ltd. Mr. Liu graduated from Beijing University of Chemical Technology, majoring in Organic Chemistry. He holds a title of Senior Engineer. In 1994 to 2004, Mr. Liu was also an executive member or vice chairman of Chinese Fermentation Industry Association and its Enzymes Branch, Chinese Detergent Association, Chinese Food Technology Association, Chinese Chemical Pharmaceutical Association International Committee, Beijing Foreign-Invested Enterprise Association and its Haidian Branch. Beyond that, Mr. Liu led the production process optimization of rifampicin, a drug for tuberculosis treatment, and achieved the highest standard nationwide. He is a major promoter of the first generation of ethanol fuel in China, as well as a successful ambassador to recruit international companies into China, including Novo Nordisk (Denmark), Bravat (Germany) and Eisai (Japan), which brought in great economical benefits. Mr. Liu is author of two books, Transnational Symbiosis and Wealth that is refound.


Dr. Bin Ye is Vice president of Shenogen Pharma Group, responsible for biomarker R&D and precision therapeutics. Dr. Ye got his PhD in Weizmann Institute of Sciences, Israel, and completed postdoctoral training in Harvard Medical School. Dr. Ye owns extensive experience in biomarker and bio-analytical for clinical trials and translational research. Prior to Shenogen, Dr. Ye was in charge of outsourcing and clinical study biomarker monitoring in Novartis. Before Novartis, Dr. Ye did research in Dana-Farber Harvard Cancer Center and Brigham and Women’s Hospital. Dr. Ye has authored/co-authored nearly 20 publications and owns 4 patents.


Dr. Peng Yong serves as Vice President of Beijing Shenogen Pharma Group,responsible for the research and development of innovative small molecule drugs. He has more than 20 years of experience in early drug discovery including target identification, lead optimization, advancement of 14 preclinical candidates into CFDA approved clinical development, and execution of phase I clinical trials of two anti-cancer candidates. Prior to joining Shenogen, Dr. Peng was general manager of Applied Pharmaceutical Science, Inc., a privately-held biopharmaceutical company from September 2017. Previously, Dr. Peng had been working at Centaurus Biopharma as vice president from 2012 to 2017, and senior director from 2010 to 2012. In those positions, Dr. Peng oversaw drug discovery programs and clinical development in oncology and metabolic diseases. From 1999 to 2009, Dr Peng worked at Discovery Neuroscience Department of Bristol-Myers Squibb Co. and DuPont Pharmaceutical Company as research investigator and senior investigator focused on centrally-controlled anti-obesity and anti-depression drug discovery. Dr. Peng received his M.D/Ph.D. from Beijing Medical University, completed his postdoctoral research at Howard Hughes Medical Institute (HHMI) on the University of Pennsylvania campus, where he discovered insulin signal transduction factor-1 (INSIG-1). He is the author of more than 20 peer-reviewed research articles, and more than 21 new drug invention patents. He was rewarded the second prize for scientific and technological progress of the State Education Commission in 1995, elected into the Recruitment Program of Global Experts, Beijing Haiju Program in 2011.

Dr. Hua Yao is Senior Director for Formulation and Translational Technology of Beijing Shenogen Pharma Group. Dr. Yao has extensive background in medicinal chemistry and pharmaceutical sciences. She worked in the field of small molecule drug delivery for over 20 years, and focused in drug formulation research and development for the past 5 years. Prior to joining Shenogen, she served as Director for Formulation R&D of Prometheon Pharma LLC. in USA, and was responsible for the development of the company’s proprietary transdermal formulation platform. Dr. Yao received her Ph.D. degree in medicinal chemistry from the University of Florida in 2007 with a focus on anti-cancer and orphan drug development and delivery methods. Subsequently, she completed two NIH-funded postdoctoral fellowships to expand her research areas in histopathology of degenerative CNS diseases and pharmacodynamics of anti-obesity peptide drugs.


说明: http://img.bj.wezhan.cn/content/sitefiles/2019585/images/11796932_%E5%91%A8%E9%AA%8F%E9%A9%AC.jpeg

Dr. Junma Zhou is Vice President of Shenogen Pharma Group, responsible for biologic drug development. Dr. Zhou graduated from Rutgers University majoring in Molecular Biology. He was trained as Postdoctoral Researcher at Johns Hopkins University, School of Medicine. Dr. Zhou owns extensive experiences and expertise in Cellular Biology, Molecular Biology, Genetic Engineering, Protein Expression and Discovery of Therapeutic Antibody. Prior to joining Shenogen, Dr. Zhou worked in WuxiApptec as Director for Antibody Discovery. Dr. Zhou had played leading roles in the establishment of Cell Line Development platform, mammalian protein expression system and humanized animal based Antibody Discovery platform etc. He led or participated as a major contributing member in several therapeutic antibody discovery projects. Some of the antibodies were already or going to be advanced into clinical phase such as the one against PD-1 and PCSK9. During his tenure in WuxiApptec, Dr. Zhou supported many small-compound drug development projects in collaboration with big pharmaceutical companies such as Merck, Pfizer, GSK, JNJ, Celgene, Takeda etc, crossing wide disease areas including oncology, infection, metabolic, cardiovascular and neurological. Dr. Zhou graduated from Nanjing University with a Bachelor degree in Biochemistry and obtained his Master degree in Genetics from Chinese Academy of Science, Beijing Institute of Genetics and Developmental Biology. 


Executive Team